PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. PATIENTS AND METHODS: Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. RESULTS: Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% +/- 13% and 70% +/- 10%, respectively. Median overall survival has not yet been reached. CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. PATIENTS AND METHODS: Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. RESULTS: Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% +/- 13% and 70% +/- 10%, respectively. Median overall survival has not yet been reached. CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
Authors: Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith Journal: J Pediatr Hematol Oncol Date: 2002 Jun-Jul Impact factor: 1.289
Authors: T A Olson; E Bayar; E Kosnik; A B Hamoudi; K J Klopfenstein; R S Pieters; F B Ruymann Journal: J Pediatr Hematol Oncol Date: 1995-02 Impact factor: 1.289
Authors: Jingying Xu; Anat Erdreich-Epstein; Ignacio Gonzalez-Gomez; Elizabeth Y Melendez; Goar Smbatyan; Rex A Moats; Michael Rosol; Jaclyn A Biegel; C Patrick Reynolds Journal: J Neurooncol Date: 2011-11-27 Impact factor: 4.130
Authors: Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson Journal: Neuro Oncol Date: 2015-04-02 Impact factor: 12.300
Authors: Vivek Verma; Catrina P Johnson; Nathan R Bennion; Abhijeet R Bhirud; Sicong Li; Rodney D McComb; Chi Lin Journal: Childs Nerv Syst Date: 2015-05-05 Impact factor: 1.475
Authors: Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2016-06-07 Impact factor: 3.621
Authors: Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman Journal: Pediatr Blood Cancer Date: 2013-02-04 Impact factor: 3.167